Simon Farrow
Neurology · Las Vegas, NVNPI 1528038619
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 144 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 32 manufacturers reported payments, led by AbbVie at 27.9% of the total. Reporting peaked in 2023 at $989 and has fallen 98.1% since, to $19 in 2025.
Across 144 payments — averaging $20.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$824
- Neurocrine Biosciences, Inc.$286
- Amgen$248
- UCB, Inc.$181
- Teva Pharmaceuticals USA, Inc.$150
- Novartis$145
- plus $1K from 26 others
Across 177 payments — averaging $3438.65 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- UCB SA$176K
- Aquestive Therapeutics, Inc.$171K
- AstraZeneca$85K
- Novo Nordisk AS$54K
- Teva Pharmaceuticals USA, Inc.$36K
- Acadia Pharmaceuticals Inc$24K
- plus $62K from 6 others
What the payments were for
- Food & beverage$2,951100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 41 | $824 |
| Neurocrine Biosciences, Inc. | 9 | $286 |
| Amgen(2 entities) | 14 | $248 |
| UCB, Inc. | 9 | $181 |
| Teva Pharmaceuticals USA, Inc. | 2 | $150 |
| Novartis | 8 | $145 |
| Genentech USA, Inc. | 7 | $136 |
| EMD Serono, Inc. | 5 | $131 |
| AstraZeneca | 4 | $94 |
| Lundbeck LLC | 4 | $87 |
| Mallinckrodt Hospital Products Inc. | 4 | $79 |
| SK Life Science, Inc. | 4 | $75 |
| Argenx US, Inc. | 4 | $58 |
| Tanabe Pharma America, Inc. | 3 | $51 |
| Acadia Pharmaceuticals Inc | 3 | $43 |
| Catalyst Pharmaceuticals, Inc. | 2 | $36 |
| Sanofi | 2 | $35 |
| Boston Scientific | 2 | $34 |
| Sumitomo Pharma America, Inc. | 2 | $28 |
| Livanova USA, Inc. | 1 | $27 |
| Zyla Life Sciences, Inc. | 2 | $23 |
| ANI Pharmaceuticals, Inc. | 1 | $21 |
| Corium, LLC | 2 | $19 |
| Mallinckrodt Enterprises LLC | 1 | $19 |
| Sunovion Pharmaceuticals Inc. | 1 | $19 |
| Biogen | 1 | $18 |
| Bristol Myers Squibb | 1 | $15 |
| Medtronic | 1 | $15 |
| Adamas Pharmaceuticals, Inc. | 1 | $15 |
| Eisai Inc. | 1 | $14 |
| Johnson & Johnson | 1 | $14 |
| Aquestive Therapeutics, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Austedo XR$130
How this compares
$2,951 in reported general payments places this provider in the 60th percentile of 145 neurology providers in Nevada.
Other neurology in Las Vegas
- Zoltan MariLas Vegas$629K
- Fan ZhangLas Vegas$398K
- le HuaLas Vegas$385K
- Mehdi AnsariniaLas Vegas$306K
- Carrie HershLas Vegas$209K
- Shanker DixitLas Vegas$137K
- Charles KamenLas Vegas$124K
- Toya MaloneLas Vegas$123K
- Nicole TheuvenetLas Vegas$120K
- Kevin XieLas Vegas$46K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.